

Special Issue

Immuno-Competent 3D Tumour Models to Predict Patient Response

Message from the Guest Editors

Developing predictive models in the laboratory for personalised cancer treatment remains the major current challenge in oncology. 3D in vitro models which recapitulate key elements of solid tumours, such as topology, heterogeneity, and microenvironmental cues, have emerged as a realistic platform for investigations into the development and evaluation of new anti-cancer therapies. Current research focuses on creating such models using patient derived cells and tissues and, importantly, in their incorporation into immunocomponent models to interrogate promising immunotherapies. This Special Issue will present advances in the field of immunocompetent 3D models to predict patient response.

Guest Editors

Prof. Dr. Marilena Loizidou

Division of Surgery and Interventional Science, University College London, London, UK

Prof. Miriam Dwek

University of Westminster, Cancer Research Group, School of Life Sciences, London, UK

Deadline for manuscript submissions

closed (30 June 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/62661

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)